Long-term Safety and Effectiveness of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Irritability-Related Behavioral Symptoms in Children and Adolescents with Fragile X Syndrome: Update to Open-Label Extension Study (ZYN2-CL-017) (S31.007)
To assess the long-term safety and effectiveness of ZYN002, a pharmaceutically produced transdermal cannabidiol gel in development for Fragile X syndrome (FXS).
Authors
- George G. Nomikos (ORCID: https://orcid.org/0000-0003-2846-1426)
- Kristen G Bzdek
- Nancy Tich
- David J. Albers (ORCID: https://orcid.org/0000-0002-5369-526X)
- Anthony Thibodeau
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209008
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00